Clinical trials play a large and growing role in the medical options patients have today and in the future. Nearly 4,000 experimental drug therapies are in active clinical trials today and that number will continue to grow as improvements are made in detecting disease, in understanding the root causes of acute and chronic illnesses, and in discovering medical innovations.
Clinical trials help to establish therapeutic innovations for vision threatening diseases. By participating with informed consent in clinical trials at the WVU Eye Institute, patients can receive new treatments before they become widely available to the public. In addition, because certain vision threatening diseases such as glaucoma tends to run in families, participating in clinical trials may one day benefit the children and grandchildren of participants.
The WVU Eye Institute clinical research program is directed by Tony Realini, MD, MPH.
To find out if you are eligible to participate in a clinical trial – contact Aimie Jones at email@example.com.
Clinical trials research opportunities include:
- Dr. Anthony Realini - St. Lucia/Dominica study to prove the effectiveness of laser as a first line of treatment for glaucoma in people of African decent
- Dr. Anthony Realini - Study on a new class of eye drops to control glaucoma
- Dr. Ghassan Ghorayeb - Study of the progression of geographic atrophy secondary to age-related Macular Degeneration
- Dr. Ghassan Ghorayeb - Study to assess the efficacy and safety of Lampalizumab administered intraviterally to patients with geographic atrophy secondary to age-related Macular Degeneration
- Dr. Ghassan Ghorayeb - Study comparing the efficacy and safety of RTH258 vs. Afibercept in subjects with neovascular age-related Macular Degeneration
- Dr. Ghassan Ghorayeb - Ocriplasmin research to better inform treatment (ORBIT)
Learn more about clinical trials in vision research here